cAMP-Epac Pathway Stimulation Modulate Connexin-43 and MicroRNA-21 Expression in Glioma Cells
Authors
Abstract:
Introduction: Malignant astrocytic gliomas are the most common and lethal brain malignancies due to their refractory to the current therapies. Nowadays, molecular targeted therapy has attracted great attention in treatment of glioma. Connexin 43 (Cx43) and micro ribonucleic acid- 21(miR-21) are among molecules that are involved in glioma development and progression. These molecules showed potential to be as target molecules with regard to glioma. Some studies have reported that cyclic adenosine monophosphate (cAMP) signaling could be effective on Cx43 and miR-21 in tissues other than in brain. We investigate possible relationship between β-adrenergic receptor and its newly described downstream, exchange protein directly activated by cAMP (Epac) signaling pathway and expression of Cx43 and miR-21 in low (1321N1) and high grade (U87MG) glioma cell lines. Methods: We treated cells with β-adrenergic agonist and Epac activator with and without adenyl cyclase inhibitor. Cx43 and miR-21 expression were measured with real-time PCR. Results: Our data showed that in 1321N1 cells, β-adrenergic-Epac pathway stimulation up and down-regulated Cx43 and miR-21 expression respectively. Whereas, in U87MG cells these interventions had no effect on Cx43 and miR-21 expression. Discussion: These findings demonstrate that low grade astrocytoma cells have better response to our pharmacological interventions.
similar resources
camp-epac pathway stimulation modulate connexin-43 and microrna-21 expression in glioma cells
introduction: malignant astrocytic gliomas are the most common and lethal brain malignancies due to their refractory to the current therapies. nowadays, molecular targeted therapy has attracted great attention in treatment of glioma. connexin 43 (cx43) and micro ribonucleic acid- 21(mir-21) are among molecules that are involved in glioma development and progression. these molecules showed poten...
full textFluoxetin Upregulates Connexin 43 Expression in Astrocyte
Introduction: Recent studies have shown that astrocytes play major roles in normal and disease condition of the central nervous system including multiple sclerosis (MS). Molecular target therapy studies in MS have revealed that connexin-43 (Cx43) and Aquaporin-4 (AQP4) contents of astrocytes undergo expression alteration. Fluoxetine had some effects in MS patients unrelated to its known antidep...
full textRegulation of connexin 43 and microRNA expression via β2-adrenoceptor signaling in 1321N1 astrocytoma cells.
Connexin 43 (Cx43) is the main gap junction protein in astrocytes and exerts the same effects on growth inhibition in astrocytoma and glioma as microRNA-146a (miR-146a) in glioma. β2-adrenergic receptor (AR) signaling modulates Cx43 expression in myocytes via components downstream of protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac). However, it remains to be elucida...
full textfluoxetin upregulates connexin 43 expression in astrocyte
introduction: recent studies have shown that astrocytes play major roles in normal and disease condition of the central nervous system including multiple sclerosis (ms). molecular target therapy studies in ms have revealed that connexin-43 (cx43) and aquaporin-4 (aqp4) contents of astrocytes undergo expression alteration. fluoxetine had some effects in ms patients unrelated to its known antidep...
full textFluoxetin Upregulates Connexin 43 Expression in Astrocyte
INTRODUCTION Recent studies have shown that astrocytes play major roles in normal and disease condition of the central nervous system including multiple sclerosis (MS). Molecular target therapy studies in MS have revealed that connexin-43 (Cx43) and Aquaporin-4 (AQP4) contents of astrocytes undergo expression alteration. Fluoxetine had some effects in MS patients unrelated to its known antidepr...
full textMy Resources
Journal title
volume 6 issue 1
pages 52- 57
publication date 2015-02
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023